Head & Neck Cancers

First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

Alan L. Ho, MD, PhD, discusses the unique elements of Oz-V that may contribute to its efficacy and tolerability in OPSCC.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

Post-treatment ctDNA positivity was associated with disease recurrence in locoregionally advanced HNSCC, including p16-positive oropharynx cancer.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

The FDA issued a CRL to RP1 plus nivolumab in advanced melanoma, accepted a NDA for the TLX101-Px imaging agent in glioma, and more.

Manish Patel, DO, discusses early evidence suggesting that AR inhibition may enhance the efficacy of immunotherapy in salivary gland cancer.

ASCO has published updates to the clinical practice guidelines for the use of systemic therapy across subsets of patients with thyroid cancer.

Frontline tislelizumab/chemotherapy yielded sustained PFS outcomes and a meaningful OS improvement vs placebo/chemotherapy in recurrent or metastatic NPC.

IMPT generated similar physical QOL scores, local disease control, gastronomy tube dependence, and OS vs IMRT in oropharyngeal squamous cell carcinoma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

First-line ficerafusp alfa at 2000 mg every 2 weeks plus pembrolizumab was deemed safe and effective in recurrent or metastatic HPV-negative HNSCC.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, breast cancer, bladder cancer, head and neck cancer, and pancreatic cancer.

Treatment with subcutaneous amivantamab plus pembrolizumab was deemed effective and safe in patients with recurrent or metastatic, PD-L1–positive HNSCC.

Ranee Mehra, MD, discusses the design of the OrigAMI-5 trial of pembrolizumab plus amivantamab and carboplatin for recurrent or metastatic HNSCC.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

Ranee Mehra, MD, discusses the toxicities associated with subcutaneous amivantamab in recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the efficacy of subcutaneous amivantamab plus pembrolizumab in patients with first-line recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the FDA breakthrough therapy designation for amivantamab and hyaluronidase for patients with recurrent or metastatic HNSCC.

Subcutaneous amivantamab monotherapy received breakthrough therapy designation from the FDA for recurrent or metastatic, HPV-unrelated HNSCC.

A group of researchers from the University of Miami sought to understand why many clinical trials in head and neck cancers fail.

Real-world data showed that adding PD-1 inhibitors to induction chemotherapy extended OS and PFS vs chemotherapy alone in frontline HNSCC.

Patients with mucosal HNSCC deemed unsuitable for curative-intent CRT achieved a 12-month in-field LRC of 80% with high-dose palliative radiation therapy.